OSU-03012 interacts with lapatinib to kill brain cancer cells

Related Experiment Video

Updated: May 18, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Laurence Booth1, Nichola Cruickshanks, Thomas Ridder

  • 1Department of Neurosurgery, Virginia Commonwealth University, Richmond, VA, USA.

Cancer Biology & Therapy
|September 20, 2012
PubMed

Insights

The drug OSU-03012 (OSU) effectively kills brain cancer cells. Combining OSU with lapatinib, an ERBB receptor inhibitor, enhances its toxicity by targeting key cell survival pathways.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The drug OSU-03012 (OSU) demonstrates potential in targeting brain cancer cells.
  • Understanding the precise mechanisms of OSU-induced cell death is crucial for optimizing its therapeutic application.

Purpose of the Study:

  • To elucidate the mechanisms by which OSU-03012 kills brain cancer cells.
  • To investigate the synergistic effects of OSU-03012 with other targeted agents, specifically ERBB inhibitors.

Main Methods:

  • Utilized cell lines and in vivo tumor models to assess drug efficacy and mechanisms.
  • Employed gene knockdown and expression studies to evaluate the roles of specific proteins (e.g., ERBB receptors, PTEN, AKT, ERK1/2, MCL-1) and apoptosis pathways.
  • Investigated the impact of drug combinations on cell viability and signaling pathways.

Main Results:

  • OSU toxicity was potentiated by HSP90 inhibitor 17-N-Allylamino-17-demethoxygeldanamycin (17AAG) and lapatinib, correlating with reduced ERBB1/2 expression.
  • Inhibition of ERBB receptors (ERBB1/2/4) with lapatinib enhanced OSU-induced cell death.
  • The combination treatment reduced AKT and ERK1/2 activity, with activated AKT and MEK1 conferring protection.
  • PTEN and mTOR signaling pathways modulated the sensitivity to the lapatinib-OSU combination.
  • Modulation of apoptosis-related proteins (CD95, NOXA, PUMA, BIK, AIF, MCL-1) influenced drug combination lethality.
  • Lapatinib and OSU synergistically suppressed tumor growth in vivo.

Conclusions:

  • Inhibition of ERBB receptor function significantly enhances the lethality of OSU-03012 in brain tumor cells.
  • Targeting ERBB receptors represents a promising strategy to improve OSU-based therapies for brain cancers.
  • The interplay between ERBB signaling, PI3K/AKT, and apoptosis pathways is critical for OSU's efficacy.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...